# Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41591-026-04762-3) · 2026-11-08 · Medicine
Page: https://themorning.science/story/hemodynamic-effects-of-semaglutide-in-individuals-with-heart-failure-with-preser-33916032645c56a8
Kind: research · Impact: low

## In brief

- Published as a placebo-controlled randomized clinical trial on semaglutide in individuals with heart failure with preserved ejection fraction (HFpEF) and obesity.
- The study examines hemodynamic effects of semaglutide in this patient group.
- The only available source is a nature.com feed entry without a summary.

## Why it matters

It adds randomized trial evidence on how semaglutide affects heart function measures in people with HFpEF and obesity, a population with limited treatment options.

## Timeline

- 2026-11-08: Listed in nature.com subject feed

## Coverage

- [Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial](https://www.nature.com/articles/s41591-026-04762-3) — Medical research : nature.com subject feeds, 2026-11-08

Tags: semaglutide, heart failure, hfpef, obesity, clinical trial, hemodynamics

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science